Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study

Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study

Background: Peripheral arterial disease (PAD) is known to be associated with high cardiovascular risk, but the individual impact of PAD presentations on risk of macrovascular and microvascular events has not been reliably compared in patients with type 2 diabetes. We aimed to evaluate the impact of...

Full description

Bibliographic Details
Main Authors:	Mohammedi, K, Woodward, M, Hirakawa, Y, Zoungas, S, Colagiuri, S, Hamet, P, Harrap, S, Poulter, N, Matthews, D, Marre, M, Chalmers, J, ADVANCE Collaborative Group
Format:	Journal article
Published:	BioMed Central 2016

Similar Items

Microvascular and macrovascular disease and risk for major peripheral arterial disease in patients with type 2 diabetes
by: Woodward, M, et al.
Published: (2016)

Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes
by: Mohammedi, K, et al.
Published: (2017)

Absence of peripheral pulses and risk of major vascular outcomes in patients with type 2 diabetes
by: Mohammedi, K, et al.
Published: (2016)

Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes
by: Kamel Mohammedi, et al.
Published: (2017-07-01)

Changes in albuminuria and the risk of major clinical outcomes in diabetes: results from ADVANCE-ON
by: Jun, M, et al.
Published: (2017)

Changes in albuminuria and the risk of major clinical outcomes in diabetes: Results From ADVANCE-ON.
by: Jun, M, et al.
Published: (2017)

Acute increases in serum creatinine after starting angiotensin-converting enzyme inhibitor-based therapy and effects of its continuation on major clinical outcomes in type 2 diabetes mellitus: the ADVANCE trial
by: Ohkuma, T, et al.
Published: (2018)

Event rates, hospital utilization, and costs associated with major complications of diabetes: a multicountry comparative analysis.
by: Philip M Clarke, et al.
Published: (2010-02-01)

The impact of level of education on vascular events and mortality in patients with type 2 Diabetes mellitus: results from the ADVANCE study
by: Blomster, J, et al.
Published: (2017)

History of lower-limb complications and risk of cancer death in people with type 2 diabetes
by: Kamel Mohammedi, et al.
Published: (2021-01-01)

Use of the waist‐to‐height ratio to predict cardiovascular risk in patients with diabetes: Results from the ADVANCE‐ON study
by: Rådholm, K, et al.
Published: (2018)

Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds
by: Zoungas, S, et al.
Published: (2012)

Haemoglobin glycation index and risk for diabetes-related complications in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial
by: van Steen, S, et al.
Published: (2018)

The relationship between plasma 8-OH-deoxyguanosine and cardiovascular disease and survival in type 2 diabetes: results from the ADVANCE study
by: Thomas, M, et al.
Published: (2018)

Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions
by: Heart Protection Study Collaborative Group
Published: (2007)

Event rates, hospital utilization, and costs associated with major complications of diabetes: a multicountry comparative analysis.
by: Clarke, P, et al.
Published: (2010)

PROX1 gene CC genotype as a major determinant of early onset of type 2 diabetes in slavic study participants from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation study.
by: Hamet, P, et al.
Published: (2017)

Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.
by: Zoungas, S, et al.
Published: (2009)

Cardiac stress and inflammatory markers as predictors of heart failure in patients with type 2 diabetes: the ADVANCE trial
by: Ohkuma, T, et al.
Published: (2017)

Side-effects and tolerability of combination blood pressure lowering according to blood pressure levels – an analysis of the PROGRESS and ADVANCE trials
by: Atkins, A, et al.
Published: (2017)

Estimating individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes
by: Woodward, M, et al.
Published: (2016)

Blood pressure variables and cardiovascular risk: new findings from ADVANCE.
by: Kengne, A, et al.
Published: (2009)

Relationship Between Plasma 8‐OH‐Deoxyguanosine and Cardiovascular Disease and Survival in Type 2 Diabetes Mellitus: Results From the ADVANCE Trial
by: Merlin C. Thomas, et al.
Published: (2018-07-01)

Self‐rated health scores predict mortality among people with type 2 diabetes differently across three different country groupings: findings from the ADVANCE and ADVANCE‐ON trials
by: Hua, X, et al.
Published: (2020)

Prognostic value of variability in systolic blood pressure related to vascular events and premature death in type 2 diabetes mellitus: The ADVANCE-ON study
by: Ohkuma, T, et al.
Published: (2017)

Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial
by: Welsh, P, et al.
Published: (2018)

Effects of the endpoint adjudication process on the results of a randomised controlled trial: the ADVANCE trial.
by: Jun Hata, et al.
Published: (2013-01-01)

Intensive glucose control improves kidney outcomes in patients with type 2 diabetes.
by: Perkovic, V, et al.
Published: (2013)

Response of 1,5‐anhydroglucitol level to intensive glucose‐ and blood‐pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial
by: Selvin, E, et al.
Published: (2019)

Outcome of major lower-limb arterial injuries presenting to a single unit in a peripheral setting in Sri Lanka
by: Parathan Sriharan, et al.
Published: (2019-01-01)

Vorapaxar for Prevention of Major Adverse Cardiovascular and Limb Events in Peripheral Artery Disease
by: Justin T. Morrison MD, et al.
Published: (2022-01-01)

Effects of blood pressure lowering on clinical outcomes according to baseline blood pressure and cardiovascular risk in patients with type 2 diabetes mellitus: the ADVANCE trial
by: Rahman, F, et al.
Published: (2019)

Associations between body mass index and the risk of renal events in patients with type 2 diabetes
by: Mohammedi, K, et al.
Published: (2018)

Major Depressive Disorder Impacts Peripheral Artery Disease Risk Through Intermediary Risk Factors
by: Gabrielle Shakt, et al.
Published: (2024-02-01)

Growth Differentiation Factor 15 Is Associated With Major Amputation and Mortality in Patients With Peripheral Artery Disease
by: Judith J. De Haan, et al.
Published: (2017-09-01)

Association of Serum Lipoprotein (a) With the Requirement for a Peripheral Artery Operation and the Incidence of Major Adverse Cardiovascular Events in People With Peripheral Artery Disease
by: Jonathan Golledge, et al.
Published: (2020-03-01)

Artificial Intelligence of Arterial Doppler Waveforms to Predict Major Adverse Outcomes Among Patients Evaluated for Peripheral Artery Disease
by: Robert D. McBane, et al.
Published: (2024-02-01)

P6.23 ARTERIAL STIFFNESS MEASUREMENT IN OBESE PATIENTS WITH A NEW DEVICE: POPMETRE®
by: M. Hallab, et al.
Published: (2013-11-01)

Peripherally derived macrophages as major phagocytes in MOG encephalomyelitis
by: Kwon, Y, et al.
Published: (2019)

Intensive glucose lowering and the risk of vascular events and premature death in patients with decreased kidney function: the ADVANCE trial
by: Ohkuma, T, et al.
Published: (2019)